NVCR

NovoCure Ltd. 10-Q Summary: Q2 2026

Business Context and Reporting Period

This summary covers the quarterly period ended June 30, 2026. NovoCure Ltd. is a global oncology company developing and commercializing Tumor Treating Fields (TTFields) devices, including Optune Gio (glioblastoma), Optune Lua (NSCLC, mesothelioma), and Optune Pax (pancreatic cancer). The company operates in a single segment with significant revenue contributions from the U.S., Germany, France, and Japan.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net revenues increased 16% in Q2 2026 compared to Q2 2025, driven by an 18% increase in active patients globally. International markets contributed $16.1 million of the growth, while the U.S. contributed $8.7 million.
• Cost Efficiency: Cost of revenues decreased 1% despite patient growth, aided by a $4.9 million tariff refund and improved array utilization. Gross margin expanded to 78% from 74%.
• Operating Expenses:
  • R&D: Decreased 8% to $51.4 million due to the completion of older clinical studies.
  • Sales & Marketing: Increased 8% to $61.7 million, driven by launch activities for Optune Pax in the U.S. and Optune Lua in Japan.
  • G&A: Decreased 9% to $39.9 million in Q2, though YTD G&A increased 42% due to a one-time non-cash expense of approximately $43.4 million related to the vesting of executive PSUs upon FDA approval of Optune Pax.
• Financial Income: Shifted from a net income of $4.5 million in Q2 2025 to a net expense of $1.9 million in Q2 2026, primarily due to lower interest income from maturing convertible notes and higher interest expenses on the senior secured credit facility.

Guidance, Outlook, and Risks

• Clinical Updates:
  • TRIDENT Trial (GBM): Did not meet the primary endpoint of overall survival improvement for early initiation of TTFields therapy.
  • METIS Trial (Brain Metastases): Met primary endpoint; PMA application submitted to FDA for Optune Mya.
  • PANOVA-4 (Pancreatic Cancer): Met primary endpoint for disease control rate; median OS was 9.7 months.
• Commercial Outlook: Management expects operating expenses to continue increasing as the company expands into new indications. The company believes current cash resources are sufficient for at least the next 12 months.
• Risks & Contingencies:
  • Geopolitical: Ongoing conflict in Israel poses supply chain risks; the company is increasing inventory and seeking second-source suppliers.
  • Tariffs: Potential impact from U.S. tariff rate changes; the company is pursuing refunds for tariffs paid under IEEPA.
  • Debt: The company has drawn $200 million of its $400 million credit facility. Options to draw Tranche C and D have expired as of June 30, 2026.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $440.6 million cash balance against projected operating losses and capital expenditures for the next 12-18 months.
• Debt Covenants: Review the terms of the $200 million senior secured credit facility, specifically interest rates (6.25% + SOFR) and repayment schedules starting Q3 2027.
• Revenue Recognition: Confirm the impact of the $43.4 million non-cash G&A charge on YTD net loss and its exclusion from future periods.
• Clinical Pipeline: Assess the commercial impact of the TRIDENT trial failure in GBM versus the positive METIS and PANOVA-4 results.
• Supply Chain Resilience: Evaluate the progress of securing second-source suppliers outside of Israel to mitigate geopolitical risks.